Analysts Set Generation Bio Co. (NASDAQ:GBIO) Target Price at $8.00

Generation Bio Co. (NASDAQ:GBIO) has earned a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.00.

Several brokerages have commented on GBIO. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a report on Thursday, March 7th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research report on Wednesday, April 10th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Panagora Asset Management Inc. bought a new position in shares of Generation Bio in the 4th quarter worth about $49,000. Kestra Private Wealth Services LLC bought a new stake in Generation Bio in the 4th quarter valued at about $50,000. SG Americas Securities LLC bought a new stake in Generation Bio in the 3rd quarter valued at about $51,000. Weiss Asset Management LP bought a new stake in Generation Bio in the 4th quarter valued at about $135,000. Finally, Los Angeles Capital Management LLC increased its position in Generation Bio by 315.6% in the 4th quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock valued at $455,000 after buying an additional 209,462 shares in the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Trading Down 0.7 %

Shares of GBIO opened at $2.83 on Friday. The company has a market capitalization of $188.17 million, a PE ratio of -1.44 and a beta of 2.78. Generation Bio has a 12 month low of $0.86 and a 12 month high of $6.98. The stock’s 50-day moving average price is $3.16 and its two-hundred day moving average price is $2.19.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.12). The business had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $3.05 million. Equities research analysts predict that Generation Bio will post -1.34 EPS for the current fiscal year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.